GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: Revuforj® | SNDX-5613 | SNDX5613
revumenib is an approved drug (FDA (2024))
Compound class:
Synthetic organic
Comment: The chemical structure for revumenib was revealed in WHO proposed INN list 126 (Jan 2022), in which it was described as an antineoplastic agent. It resolved to Syndax Pharmaceuticals' SNDX-5613 via a PubChem match on SMILES. SNDX-5613 inhbits the Menin-KMT2A protein-protein interaction (binding directly to menin), as a strategy that was originally proposed to treat acute leukemias that are driven by proleukemogenic KMT2A rearrangements [1].
Additional menin inhibitors in development include bleximenib (JNJ-75276617), ziftomenib (KO-539), emilumenib (DS-1594a), enzomenib (DSP-5336) and icovamenib (BMF-219). |
|
|||||||||||||||||||||||||||||||||||
Classification ![]() |
|
| Compound class | Synthetic organic |
| Approved drug? | Yes. US FDA (2024) |
International Nonproprietary Names ![]() |
|
| INN number | INN |
| 11657 | revumenib |
Synonyms ![]() |
| Revuforj® | SNDX-5613 | SNDX5613 |
Database Links ![]() |
|
| CAS Registry No. | 2169919-21-3 (source: WHO INN list) |
| ChEMBL Ligand | CHEMBL4650827 |
| GtoPdb PubChem SID | 461663438 |
| PubChem CID | 132212657 |
| RCSB PDB Ligand | OQ4 |
| Search Google for chemical match using the InChIKey | FRVSRBKUQZKTOW-YOCNBXQISA-N |
| Search Google for chemicals with the same backbone | FRVSRBKUQZKTOW |
| Search PubMed clinical trials | revumenib |
| Search PubMed titles | revumenib |
| Search PubMed titles/abstracts | revumenib |
| UniChem Compound Search for chemical match using the InChIKey | FRVSRBKUQZKTOW-YOCNBXQISA-N |
| UniChem Connectivity Search for chemical match using the InChIKey | FRVSRBKUQZKTOW-YOCNBXQISA-N |
Product supplier links are provided as a service to assist in identifying commercial suppliers of reagents that are mentioned on the IUPHAR/BPS Guide to PHARMACOLOGY database website, and do not imply their endorsement by NC-IUPHAR.
Links are provided in return for sponsorship, used to fund improvements to this database. The sponsorship account is managed and audited by the University of Edinburgh, a charitable body registered in Scotland, SC005336. If you are interested in sponsoring the database, please contact us.
✖|
Revumenib (links to external site)
Cat. No. HY-136175 |